The management of testicular cancer continues to evolve, with advances in diagnostics, risk stratification, and multimodal treatment shaping contemporary clinical practice. At the 41st Annual Congress ...
FIT-001 enrolled ccRCC patients with prior immunotherapy, KPS ≥70, and prior cabozantinib exposure, using darlifarnib 3/5/8 mg QD (7-on/7-off) plus cabozantinib 40/60 mg. Antitumor activity was ...
Alex Tatem, MD, explains that hyaluronic acid penile injections add temporary, measurable girth by safely distributing a reversible filler within soft tissue, though outcomes depend heavily on ...
VYBRIQUE is a sildenafil oral film formulated for discreet, water-free administration, aiming to reduce use barriers for patients for whom privacy and convenience influence ED treatment adherence. A ...
The first-ever guideline on genitourinary syndrome of menopause (GSM) was released, providing evidence-based guidance for managing this condition in urologic care. The FDA removed the black box ...
IsoPSA, a blood-based test, aids in diagnosing high-grade prostate cancer by analyzing PSA protein structural variants. FDA approval was based on a large-scale, prospective study and other validation ...
AVZO-103 has received fast track designation for treating urothelial carcinoma, enabling accelerated development and review processes. The phase 1/2 trial will assess AVZO-103's safety, tolerability, ...
The ASPIRE trial evaluates the addition of docetaxel to standard hormone therapy and apalutamide in metastatic castration-sensitive prostate cancer. Approximately 1200 participants will be enrolled ...
Nocturnal enuresis affects millions, including adolescents and adults, and is not the child's fault but a sleep-related condition outside conscious control. Current treatments, including behavioral ...
Neuspera's iSNM system provides a battery-free alternative to traditional SNM, reducing complications and surgeries for UUI patients. The SANS-UUI trial showed 84.2% of patients achieved at least a 50 ...
Expert panel developed guidelines for onabotulinumtoxinA use in OAB, emphasizing patient experience and compliance. Recommendations cover patient counseling, pre-procedure urinalysis, antibiotic use, ...
Panelists discuss the expanding treatment options for BCG-unresponsive high-risk non–muscle-invasive bladder cancer, highlighting the benefits and limitations of FDA-approved therapies like ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results